David Lawrence

David Lawrence has extensive experience in the biotechnology and healthcare sectors, currently serving as NXD at EnteroBiotix since April 2022. Previously, David held the position of CFO at Valneva from August 2017 to December 2021, leading significant financial operations, including a successful US IPO exceeding $100 million in 2021. Other notable roles include CEO (Consultant) at Sentinext Therapeutics, Non-Executive Chairman at Ambicare Health, and CEO at Tayside Flow Technologies, where David focused on innovative technologies and commercialization strategies. David's career also includes positions at Acambis plc as CFO and involvement with multiple other companies within the biotechnology landscape. David holds a BA in Business Economics from the University of the West of Scotland.